BackEikon Therapeutics Common Stock Overview

Eikon Therapeutics Common Stock Long Term Debt

Track Eikon Therapeutics Common Stock's long-term debt ($250M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$245.09M

Peer average / median

Loading

Eikon Therapeutics Common Stock Long Term Debt History

Loading

Eikon Therapeutics Common Stock vs. peers: Long Term Debt Comparison

Loading

Eikon Therapeutics Common Stock Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Eikon Therapeutics Common Stock (EIKN) FAQ

As of the most recent data (March 2026), EIKN shows a long-term debt of $250M. Scroll down for historical charts and peer comparison views.

Tracking EIKN's long-term debt over time shows whether Eikon Therapeutics Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $250M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Eikon Therapeutics Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $250M) with ownership activity and broader fundamentals.

Eikon Therapeutics Common Stock's long-term debt is $250M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.